NaiVec Confirms Efficacy of 'Inflammation-Control Tissue Regeneration Therapy' in Animal Trials

[Asia Economy Reporter Hyunseok Yoo] Naivec, a peptide fusion bio-specialized company, announced on the 27th that it confirmed the anti-inflammatory healing effect in animal experiments (adult dog experiments) of the "inflammation control-based tissue regeneration therapeutic" developed for the first time in the world through joint research with the Korea Photonics Technology Institute and Seoul National University Dental Hospital.

The inflammation control tissue regeneration therapeutic developed by Naivec is evaluated as a highly expandable bio-material that can heal various inflammatory diseases such as periodontal disease, arthritis, muscle regeneration, and liver regeneration, and regenerate tissues.

In this adult dog experiment, Naivec confirmed the efficacy of the peptide-based tissue regeneration therapeutic, which penetrates cells, in completely blocking the progression of inflammation within periodontal tissues. Based on this efficacy, it is expected to become a new mechanism tissue regeneration therapeutic that blocks intracellular inflammatory factors and promotes the regeneration of cell tissues.

Naivec plans to first commercialize the tissue regeneration therapeutic as an injectable "medical device" for periodontal tissue regeneration. The company expects to secure global competitiveness in both regenerative materials and therapeutic fields as it is currently developing pharmaceuticals in parallel.

A Naivec official said, "Based on the high-purity collagen and peptide functional active substances developed in-house, research and development is progressing smoothly with close consultation and active support from the ‘Pan-Ministry Full-Cycle Medical Device R&D Project Group’," adding, "Since the anti-inflammatory control and tissue regeneration efficacy were verified in this adult dog experiment, we plan to enter clinical trials next year."

He continued, "The inflammation control-based tissue regeneration therapeutic involved domestic and international clinical researchers from the planning stage, and commercialization is underway in cooperation with global companies. We have already secured purchase commitments from the world’s number one global implant company," adding, "Since it is being developed as both a medical device and a pharmaceutical, we expect to fully enter the rapidly growing regenerative medical market, which grows at about 20% annually."

Naivec was selected last October in the ‘4th Industrial Revolution and Future Medical Environment Leading Project’ field supported by the ‘Pan-Ministry Full-Cycle Medical Device R&D Project Group.’ Naivec is jointly researching and developing peptide and high-purity collagen functional active substances in convergence with the Korea Photonics Technology Institute and Seoul National University Dental Hospital to develop overall tissue regeneration therapeutics, materials, and medical devices for muscle regeneration, liver regeneration, and more.